Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics (NASDAQ: TNYA) has granted stock options to two new non-executive employees as employment inducements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) has granted stock options to two new non-executive employees as employment inducements. The options allow purchase of 12,000 total shares at $1.97 per share, matching the November 15, 2024 closing price. These ten-year options vest over four years, with 25% vesting after one year and the remainder vesting monthly at 1/48th of the original shares. The grants were made under the company's 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Rule 5635(c)(4).
Details
News Market Reaction – TNYA
The recorded move for TNYA in the trading session of this news was +10.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement material to each new employee’s acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.